29.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Axogen Inc Borsa (AXGN) Ultime notizie
Squarepoint Ops LLC Purchases 348,950 Shares of AxoGen, Inc. $AXGN - MarketBeat
With Axogen Stock Surging, Have You Considered The Downside? - Trefis
Would You Still Hold Axogen Stock If It Fell Another 30%? - Trefis
Should FDA Biologic Approval of AVANCE Nerve Scaffold Require Action From Axogen (AXGN) Investors? - simplywall.st
Is Axogen Stock Built to Withstand More Downside? - Trefis
Leerink Partners raises AxoGen stock price target to $40 on BLA approval - Investing.com Nigeria
Can Axogen Stock Recover If Markets Fall? - Trefis
Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN) - GuruFocus
Trade Alert: President Of Axogen Michael Dale Has Sold Stock - simplywall.st
Armistice Capital LLC Boosts Holdings in AxoGen, Inc. $AXGN - MarketBeat
Michael Dale Sells 61,463 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
Paul Thomas Sells 21,399 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
John Johnson Sells 21,686 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
AxoGen (NASDAQ:AXGN) CFO Sells $454,053.72 in Stock - MarketBeat
Insider Sell: Paul Thomas Sells 21,399 Shares of Axogen Inc (AXG - GuruFocus
Axogen Insider Sold Shares Worth $1,390,393, According to a Recent SEC Filing - marketscreener.com
Axogen Insider Sold Shares Worth $633,710, According to a Recent SEC Filing - marketscreener.com
Legal & General Group Plc Purchases 83,175 Shares of AxoGen, Inc. $AXGN - MarketBeat
CFO Hartley Files To Sell 14,387 Of Axogen Inc [AXGN] - TradingView
H.C. Wainwright raises AxoGen stock price target to $39 after FDA approval - Investing.com India
AxoGen (NASDAQ:AXGN) Trading Down 4.7%What's Next? - MarketBeat
H.C. Wainwright raises AxoGen stock price target to $39 after FDA approval By Investing.com - Investing.com South Africa
(AXGN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
AxoGen approves new CFO compensation and agreement - MSN
Prudential Financial Inc. Trims Stake in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN): Reassessing Valuation After FDA Biologics License Approval for AVANCE - Sahm
Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq
AxoGen Secures FDA Approval for Avance Nerve Scaffold - The Globe and Mail
Canaccord Genuity Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AxoGen Approves New CFO Compensation and Agreement - TipRanks
AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Bu - GuruFocus
AXGN Sees Enhanced Price Target by HC Wainwright & Co. Analyst Y - GuruFocus
Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025 - simplywall.st
AxoGen (NASDAQ:AXGN) Shares Gap UpHere's What Happened - MarketBeat
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity - Investing.com Nigeria
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity By Investing.com - Investing.com South Africa
AxoGen, Inc. $AXGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
Will Axogen Inc. stock maintain growth storyWeekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Bu - GuruFocus
Jefferies Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AXGN: Lake Street Maintains "Buy" Rating and Raises Price Target to $40.00 | AXGN Stock News - GuruFocus
Why Is Axogen Stock Soaring Thursday?Axogen (NASDAQ:AXGN) - Benzinga
AxoGen stock price target raised to $36 from $27 at Raymond James By Investing.com - Investing.com South Africa
AxoGen stock price target raised to $36 from $27 at Raymond James - Investing.com Nigeria
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval By Investing.com - Investing.com Nigeria
Why Is AXGN Stock Rising Today? - Stocktwits
Axogen's Avance secures FDA approval for nerve repair - BioWorld MedTech
FDA approves Axogen's nerve repair graft - Reuters
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval - Investing.com
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval - Investing.com Nigeria
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval By Investing.com - Investing.com South Africa
Axogen, Inc. (AXGN) Stock: FDA Approval Boosts Avance as a Leading Nerve Repair Solution - parameter.io
Mizuho Begins Coverage on AxoGen (NASDAQ:AXGN) - MarketBeat
FDA Biologic Approval For AVANCE Might Change The Case For Investing In Axogen (AXGN) - simplywall.st
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):